Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Hammad

Showing results (351-360 of 353) with videos related to

Pageof 36
Sort By:
You have reached the last page of results.This site can display upto 353 results.
Molecular Genetics & Genomic Medicine|October 5, 2021
Chromosome 9p terminal deletion in nine Egyptian patients and narrowing of the critical region for trigonocephalyAmal M Mohamed, Alaa K Kamel, Maha M Eid, et al.
Clinical Transplantation|March 26, 2021
Better outcome of COVID-19 positive kidney transplant recipients during the unremitting stage with optimized anticoagulation and immunosuppressionTorki M AlOtaibi, Osama A Gheith, Mohammed M Abuelmagd, et al.
Drug Safety|August 5, 2025
Teratogenic Risk Impact Mitigation (TRIM): Development of Explicit Criteria to Facilitate Decisions Regarding Teratogenic Risk Mitigation StrategiesCeleste L Y Ewig, Yanning Wang, Nicole E Smolinski, et al.
Pageof 36

Showing results (351-360 of 353) with videos related to

Sort By:
Pageof 36
You have reached the last page of results.This site can display upto 353 results.
Molecular Genetics & Genomic Medicine|October 5, 2021
Chromosome 9p terminal deletion in nine Egyptian patients and narrowing of the critical region for trigonocephalyAmal M Mohamed, Alaa K Kamel, Maha M Eid, et al.
Clinical Transplantation|March 26, 2021
Better outcome of COVID-19 positive kidney transplant recipients during the unremitting stage with optimized anticoagulation and immunosuppressionTorki M AlOtaibi, Osama A Gheith, Mohammed M Abuelmagd, et al.
Drug Safety|August 5, 2025
Teratogenic Risk Impact Mitigation (TRIM): Development of Explicit Criteria to Facilitate Decisions Regarding Teratogenic Risk Mitigation StrategiesCeleste L Y Ewig, Yanning Wang, Nicole E Smolinski, et al.
Pageof 36